Novel N7-Arylmethyl Substituted Dinucleotide mRNA 5′ cap Analogs: Synthesis and Evaluation as Modulators of Translation
Authors:
- Radoslaw WojcikRadoslaw Wojcik
- Marek R. BaranowskiMBMarek R. Baranowski
- Lukasz MarkiewiczLMLukasz Markiewicz
- Dorota KubackaDKDorota Kubacka
- Marcelina BednarczykMBMarcelina Bednarczyk
- Natalia BaranNBNatalia Baran
- Anna WojtczakAWAnna Wojtczak
- Pawel J. SikorskiPSPawel J. Sikorski
- Joanna ZuberekJZJoanna Zuberek
- Joanna KowalskaJKJoanna Kowalska
- Jacek JemielityJJJacek Jemielity
Open Access
- 16 November 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (11) , 1941
Abstract
Dinucleotide analogs of the messenger RNA cap (m7GpppN) are useful research tools and have potential applications as translational inhibitors or reagents for modification of in vitro transcribed mRNAs. It has been previously reported that replacing the methyl group at the N7-position with benzyl (Bn) produces a dinucleotide cap with superior properties. Here, we followed up on this finding by synthesizing 17 novel Bn7GpppG analogs and determining their structure–activity relationship regarding translation and translational inhibition. The compounds were prepared in two steps, including selective N7-alkylation of guanosine 5′-monophosphate by arylmethyl bromide followed by coupling with imidazole-activated GDP, with total yields varying from 22% to 62%. The compounds were then evaluated by determining their affinity for eukaryotic translation initiation factor 4E (eIF4E), testing their susceptibility to decapping pyrophosphatase, DcpS—which is most likely the major cellular enzyme targeting this type of compound—and determining their translation inhibitory properties in vitro. We also synthesized mRNAs capped with the evaluated compounds and tested their translational properties in A549 cells. Our studies identified N7-(4-halogenbenzyl) substituents as promising modifications in the contexts of either mRNA translation or translational inhibition. Finally, to gain more insight into the consequences at the molecular level of N7-benzylation of the mRNA cap, we determined the crystal structures of three compounds with eIF4E.Keywords
Funding Information
- Narodowe Centrum Nauki (2019/33/B/ST4/01843, UMO-2017/24/C/NZ1/00169, UMO-2016/21/N/ST4/03750)
- Fundacja na rzecz Nauki Polskiej (TEAM/2016_2/13)
This publication has 41 references indexed in Scilit:
- Design, synthesis and evaluation of analogs of initiation factor 4E (eIF4E) cap-binding antagonist Bn7-GMPEuropean Journal of Medicinal Chemistry, 2010
- Features and development of CootActa Crystallographica Section D Structural Biology, 2010
- PHENIX: a comprehensive Python-based system for macromolecular structure solutionActa Crystallographica Section D Structural Biology, 2010
- XDSActa Crystallographica Section D Structural Biology, 2010
- Crystallization of eIF4E complexed with eIF4GI peptide and glycerol reveals distinct structural differences around the cap-binding siteCell Cycle, 2009
- Crystallographic and Mass Spectrometric Characterisation of eIF4E with N7-alkylated Cap DerivativesJournal of Molecular Biology, 2007
- Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cellsRNA, 2007
- Phasercrystallographic softwareJournal of Applied Crystallography, 2007
- Cap‐free structure of eIF4E suggests a basis for conformational regulation by its ligandsThe EMBO Journal, 2006
- Biophysical Studies of eIF4E Cap-binding Protein: Recognition of mRNA 5′ Cap Structure and Synthetic Fragments of eIF4G and 4E-BP1 ProteinsJournal of Molecular Biology, 2002